Fig. 3From: The expansion of targetable biomarkers for CAR T cell therapyClinical trial Biomarkers as of May 2018 by year. The expansion of CAR targets is shown as the diversity and number of clinical trials has exponentially increased from 2012. Not only are there more clinical trials utilizing CAR T cell therapy, there are also more targets being evaluatedBack to article page